SPML FY26 Profit ₹1303.29 Lakh; Revenue ₹7528.51 Lakh

Speciality Medicines Limited (SPML) announced its audited standalone financial results for the half-year and full financial year ended March 31, 2026. For the full year, the company reported Revenue from Operations of ₹7,528.51 Lakh and a Profit for the period of ₹1,303.29 Lakh. For the half-year ended March 31, 2026, Revenue from Operations stood at ₹4,478.34 Lakh, with a Profit for the period of ₹818.27 Lakh. The Board of Directors approved these results, along with the audited standalone financial statements, and noted the utilization of Initial Public Issue (IPO) proceeds in line with the prospectus. The Auditor's Report was issued with an unmodified opinion.